AbbVie's SWOT analysis: stock outlook amid Humira erosion and pipeline growth
AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...
Crain's Chicago Business3h
Two more AbbVie drugs put on the Medicare negotiation list
Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...
AbbVie price target lowered to $212 from $221 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...
Optimistic Outlook on AbbVie’s Emraclidine Strategy: A High-Reward Investment Opportunity
Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...
AbbVie stock target cut, keeps Buy rating on growth outlook
Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...
NJBIZ2h
Wegovy, Ozempic targeted for Medicare price negotiations
The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.